24-sulfoximine vitamin D 3 compounds

Details 24-sulfoximine vitamin D 3 compounds 24-sulfoximine vitamin D 3 compounds

2011-07-05

2011-07-05

Badio, Barbara P (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

9,10-seco- cyclopentanohydrophenanthrene ring system doai

Reexamination Certificate

active

07973024

ABSTRACT:
The present invention provides novel sulfoximine compounds, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1α,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.

REFERENCES:
patent: 4481198 (1984-11-01), DeLuca et al.
patent: 6043386 (2000-03-01), Posner et al.
patent: 6380408 (2002-04-01), Posner et al.
patent: 0386793 (1990-12-01), None
patent: WO 9115475 (1991-10-01), None
patent: WO 9410139 (1994-05-01), None
patent: WO 9414766 (1994-07-01), None
patent: WO 0059513 (2000-10-01), None
Schroder E. et al., “Arzneimittelchemie passage”, Arzneimittelchemie Grundlagen Nerven, 1976, pp. 30-33, XP002186820.
Greising, D. M. et al., “A-Ring Analogues of 1,25-(OH)2D3With Low Affinity for the Vitamin D Receptor Modulate Chondrocytes via Membrane Effects That Are Dependent on Cell Maturation,” Journal of Cellular Physiology, 1997, pp. 357-367, vol. 171.
Hartman, R. W. et al., “Synthesis and Evaluation of Novel Steroidal Oxime Inhibitors of P450 17 (17α-Hydroxlase/C17-20-Lyase) and 5α-Reductase Types 1 and 2,” Journal of Medical Chemistry, 2000, pp. 4266-4277, vol. 43, No. 22.
Kensler, T. W. et al., “Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis,” Carcinogenesis, 2000, pp. 1341-1345, vol. 21, No. 7.
Posner, G. H. et al., “Sterocontrolled Synthesis of a Trihydroxylated A Ring as an Immediate Precursor to 1α,2α,25-Trihydroxyvitamin D3,” J. Org. Chem., 1991, pp. 4339-4341, vol. 56.
Posner, G. H. et al., “New Vitamin D3Derivatives with Unexpected Antiproliferative Activity: 1-(Hydroxymethyl)-25-hydroxyvitamin D3Homologs,” J. Med. Chem., 1992, pp. 3280-3287, vol. 35.
Dai, H et al., “Synthetic Approaches to Vitamin D,” Synthesis, 1994, pp. 1383-1397.
Posner, G. H. et al., “Sterocontrolled Total Synthesis of Calcitriol Derivatives: 1,25-Dihydroxy-2-(4′- hydroxybutyl)vitamin D3Analogs of an Osteoporosis Drug,” J. Org. Chem., 1994, pp. 7855-7861, vol. 59.
Posner, G. H. et al., “1α,25-Dihydroxyvitamin D3Hybrid Analogs with Structural Changes at Both the A-Ring and the C,D-Ring Side-chain. 11,” Bioorganic & Medicinal Chemistry Letters, 1995, pp. 2163-2168, vol. 5, No. 18.
Posner, G. H. et al., “1α,25-Dihydroxyvitamin D3Hybrid Analogs with Structural Changes at Both the A-Ring and the C,D-Ring Side-chain,” Bioorganic & Medicinal Chemistry Letters, 1994, pp. 2919-2924, vol. 4, No. 24.
Posner, G.H. et al., “1α,25-Dihydroxyvitamin D3Analogs Featuring Aromatic and Heteroaromatic Rings: Design, Synthesis and Preliminary Biological Testing,” J. Med. Chem., 1995, pp. 4529-4537, vol. 38.
Posner, G. H., “New vitamin D analogues,” Nephrol. Dial. Transplant., 1996, pp. 32-36, vol. 11, Suppl. 3.
Peleg, S. et al., “A 20-Epi Side Chain Restores Growth-Regulatory and Transcriptional Activities of an A Ring-Modified Hybrid Analog of 1α,25-Dihydroxyvitamin D3Without Increasing Its Affinity to the Vitamin D Receptor,” Journal of Cellular Biochemistry, 1996, pp. 149-161, vol. 63.
Posner, G. H. et al., “Antiproliferative Hybrid Analogs of the Hormone 1α,25-Dihydroxyvitamin D3,: Design, Synthesis, and Preliminary Biological Evaluation,” J. Org. Chem., 1997, pp. 3299-3314, vol. 62.
Posner, G. H. et al., “Noncalcemic, Antiproliferative, Transcriptionally Active, 24-Fluroinated Hybrid Analogues of the Hormone 1α,25-Dihydroxyvitamin D, Synthesis and Preliminary Biological Evaluation,” Journal of Medicinal Chemistry, 1998. pp. 3008-3014 vol. 41 No. 16.
Peleg, S. et al., “Differential Use of Transcription Activation Function 2 Domain of the Vitamin D Receptor by 1,25-Dihydroxyvitamin D, and It's A Ring-Modified Analogs,” Molecular Endocrinology, 1998, pp. 525-535, vol. 12, No. 4.
Posner, G. H. et al., “Vitamin D Endocrine System Structural, Biological, Genetic and Clinical Aspects,” Proceedings of Eleventh Workshop on Vitamin D, Nashville, Tennessee, May 27-Jun. 1, 2000, pp. 3-10, Norman A. W et al. Eds. Printing and Reprographics University of California, Riverside, USA.
Posner, G. H. et al., “A Non-Calcemic Sulfone Version of the Vitamin D, Analogue Seocalcitol (EB 1089): Chemical Synthesis, Biological Evaluation and Potency Enhancement of the Anticancer Drug Adramycin,” Bioorganic & Medicinal Chemistry 2001, pp. 2365-2371, vol. 9.
Hofer, H. et al., “Biological Effects of 1α-Hydroxy-and 1β-(Hydroxymethyl)-Vitamin D Compounds Relevant for Potential Colorectal Cancer Therapy,” The Journal of Pharmacology and Experimental Therapeutics, 1999, pp. 450-455, vol. 291, No. 2.
Boyan, B. D. et al., “1,25-(OH)2D3, modulates growth plate chondrocytes via membrane receptor-meiated protein kinase C by a mechanism that involves changes in phospholipid metabolism and the action of arachidonic acid and PGE2,” Steroids, 1999, pp. 129-136, vol. 64.
Posner, G. H. et al., “2,2-Disubstituted Analogues of the Natural Hormone 1α,25-Dihydroxyvitamin D3: Chemistry and Biology,” Bioorganic & Medicinal Chemistry, 2002, pp. 2353-2365, vol. 10.
Hatcher, M. A. et al., “[3,3]-Sigmatropic rearrangements: short, stereo controlled syntheses of functionalized vitamin D3side-chain units,” Tetrahedron letters, 2002, pp. 5009-5012, vol. 43.
Guyton, K. Z. et al., “Vitamin D and Vitamin D Analogs as Cancer Chemopreventive Agents,” Nutrition Reviews, 2003, pp. 1-12, vol. 61, No. 7.
Hilpert, H. et al., “Novel versatile approach to an enantiopure 19-nordes-C,D vitamin D3derivative,” Tetrahedron, 2001, pp. 681-694, vol. 57.
Posner, G. H. et al., “2-Fluoroalkyl A-Ring Analogs of 1,25-Dihydroxyvitamin D3-Sterocontrolled Total Synthesis via Intramolecular and Intermolecular Diels-Alder Cycloadditions. Preliminary Biological Testing,” J. Org. Chem., 1995, pp. 4617-4628, vol. 60.
Peleg, S. et al., “Vitamin D Analogs as Modulators of Vitamin D Receptor Action,” Current Topics in Medicinal Chemistry, 2003, pp. 1-20, vol. 3.
Guyton, K. Z. et al., “Cancer Chemoprevention Using Natural Vitamin D and Synthetic Analogs,” Annu. Rev. Pharmacol. Toxicol., 2001, pp. 421-442, vol. 41.
Posner, G. H. et al., “Conceptually New Sulfone Analogues of the Hormone 1α,25-Dihydroxyvitamin D3: Synthesis and Preliminary Biological Evaluation,” Journal of Medicinal Chemistry, 1999, pp. 3425-3435, vol. 42, No. 18.
Posner, G. H. et al., “Conceptually New 20-epi-22-Oxa Sulfone Analogues of the Hormone 1α, 25-Dihydroxyvitamin D3: Synthesis and Biological Evaluation,” Journal of Medicinal Chemistry, 2000, pp. 3581-3586, vol. 43, No. 19.
Posner, G. H. et al., “Conceptually New Low-Calcemic Oxime Analogues of the Hormone 1α,25-Dihydroxyvitamin D3: Synthesis and Biological Testing,” J. Med. Chem., 2002, pp. 1723-1730, vol. 45.
Crawford, K. R., “Design, Synthesis, and Preliminary Biological Evaluation of Analogs of 1α,25-Dihydroxyvitamin D3: Modifications to the A-Ring and C,D-Ring Side Chain,” Ph.D. Thesis, Johns Hopkins University, 2001, pp. 13-56 and 51-55.
Wang, Q., “Part I: Noncalcemic, Antiproliferative, Transcriptionally Active Hybrid Analogs of the Hormone 1α,25-Dihydroxyvitamin D3: Design, Synthesis, and Preliminary Biological Evaluation,” Ph.D. Thesis, Johns Hopkins University, 2000, pp. 39-57.
Shuster et al., “Selective Inhibition of Vitamin D Hydroxylases in Human Keratinocytes,” Steroids, 2001, pp. 409-422, vol. 66.
Haider, S., et al., “Synthesis and Evaluation of Steroidal Hydroxamic Acids as Inhibitiors of P450 17 (17 α-Hydroxylase/C17-20-Lyase),ȁ

Affiliated with

Also associated with

Rating

24-sulfoximine vitamin D 3 compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 24-sulfoximine vitamin D 3 compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 24-sulfoximine vitamin D 3 compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2650257